Stock of the Day

Today's Trend

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) shares have recently been volatile as investors weigh a bullish analyst upgrade against a more cautious broader analyst view and the company’s upcoming cancer-data catalyst.

• Leerink upgraded Zentalis to Outperform and set an $8 price target, replacing its Market Perform rating. Based on the referenced price of $2.67, the target implies approximately 200% upside, providing a significant boost to investor sentiment. Leerink upgrades Zentalis Pharmaceuticals to Outperform
• The upgrade helped drive a sharp near-term rebound in ZNTL shares, with coverage noting that the stock gained more than 10% following Leerink’s recommendation. Zentalis stock gains after Leerink upgrade
• Investors are also looking ahead to October cancer data, which could provide an important readout for Zentalis’ clinical pipeline and serve as a near-term catalyst if results support the company’s drug-development prospects. Zentalis heads toward October cancer data
• Wells Fargo maintained a Hold rating, while the broader brokerage consensus remains Hold. This limits the strength of the bullish signal from Leerink and highlights continued uncertainty around Zentalis’ clinical and financial outlook. Wells Fargo gives Zentalis a Hold rating
• Zentalis remains a speculative biotech, with shares still well below their 50-day and 200-day moving averages. The company also recently reported a quarterly loss that exceeded analysts’ expected loss, reinforcing concerns about execution and the need for positive clinical results.